LivaNova wins FDA PMA for aura6000 sleep apnea implant

LivaNova has won US FDA premarket approval for the aura6000 system, giving the company an entry into the obstructive sleep apnea device market with an implantable hypoglossal nerve stimulation therapy for adults with moderate to severe disease. According to FDA’s PMA record, the agency approved the device on March 18, 2026, for patients with an AHI of 15 to 65 who have failed, do not tolerate, or are ineligible for standard treatments including PAP, oral appliances, or pharmacotherapy. (accessdata.fda.gov)

The approval follows a multiyear development path. LivaNova announced FDA approval of the investigational device exemption study in June 2021, launching the OSPREY trial in the US as a randomized, controlled study of the aura6000 system in adults with moderate to severe OSA. ClinicalTrials.gov describes OSPREY as a multicenter, prospective trial in which all qualifying participants were implanted and then randomized 2:1 to active stimulation or control, with therapy starting at month 1 in the active arm and month 7 in the control arm, primary evaluation at month 7, and follow-up through month 13. (investor.livanova.com)

By May 2025, LivaNova said it had completed its PMA submission after meeting the primary safety and efficacy endpoints in OSPREY. In that same update, the company reported 12-month top-line results showing a 65% active patient responder rate, defined as at least a 50% reduction in AHI with AHI below 20, plus median reductions of 68% in both AHI and oxygen desaturation index. The company also said those results extended to patients with severe OSA, elevated body mass index, and high predicted risk of complete concentric collapse, a subgroup that matters because CCC has historically limited eligibility for some hypoglossal nerve stimulation approaches. (investor.livanova.com)

That CCC point is where the approval appears to stand out most. In its March 19, 2026 announcement, LivaNova said aura6000 is the first and only hypoglossal nerve stimulation therapy approved in the US without contraindication or warning language related to complete concentric collapse. The company also said the approved labeling does not require pre-implant drug-induced sleep endoscopy. FDA’s PMA entry confirms the approved indication and patient population, while LivaNova’s announcement frames the broader commercial message: a device intended to expand access beyond the narrower selection criteria seen with earlier systems. (nasdaq.com)

LivaNova’s release included additional efficacy detail from OSPREY. The randomized controlled trial met its primary endpoints at 6 months versus control, with reported reductions in both AHI and ODI and improvements in patient-reported sleep disturbance. At month 7, median AHI in the treatment group fell from 34.3 events per hour at baseline to 11.6, with a reported between-group median difference of negative 18.9 events per hour. The company also said 69% of treated patients achieved at least a 25% reduction in ODI at month 7, compared with 38% in controls, and that median ODI fell from 35 to 13 events per hour. By month 13, median AHI was 11.0 in the active treatment group, while the former control group, after activation, was at 20.9. The company also said OSPREY enrolled patients whose baseline OSA severity and BMI were representative of the broader OSA population seen in practice. Those claims come from company communications, so they’re best read as important but still partly dependent on fuller peer-reviewed publication and the FDA summary materials. (nasdaq.com)

Industry reaction has centered on market access and differentiation. LivaNova said the next-generation, MRI-compatible device is expected to launch in the first half of 2027, pending FDA supplement review. The company has also described that planned version as adding secure remote configuration and a rechargeable battery. Third-party coverage from Medical Device Network, syndicated via Yahoo, similarly reported that the approval sets up a 2027 launch timeline. That suggests this PMA is a major regulatory milestone, but not the end of the commercial rollout story. (nasdaq.com)

Why it matters: For veterinary professionals, this isn’t a direct animal health development, but it is a useful regulation case study in how FDA handles Class III implantable devices: pivotal randomized evidence, tightly defined labeling, and mandatory post-approval follow-up. FDA’s post-approval studies database already lists a continued follow-up study tied to the aura6000 PMA, reinforcing that long-term safety and effectiveness data remain part of the approval package. More broadly, the decision shows how device makers are trying to widen eligibility in sleep-related neuromodulation by addressing historical exclusion criteria such as CCC, while also competing on features like MRI compatibility, rechargeability, and remote programming in next-generation systems. (accessdata.fda.gov)

What to watch: The next milestones are publication of fuller FDA summary documents and peer-reviewed trial data, any PMA supplement tied to MRI compatibility and final commercial configuration, and early signals on reimbursement, surgeon adoption, and whether broader labeling translates into broader real-world use in 2027. (nasdaq.com)